Rabeprazole

Revision as of 15:52, 13 January 2015 by Rabin Bista (talk | contribs)
Jump to navigation Jump to search

Rabeprazole
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rabin Bista, M.B.B.S. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Rabeprazole is a proton-pump inhibitor (PPI) that is FDA approved for the treatment of Gastroesophageal Reflux Disease (GERD), Duodenal Ulcers, Helicobacter pylori Eradication, Pathological Hypersecretory Conditions including Zollinger-Ellison Syndrome.. Common adverse reactions include pain, flatulence, infection, constipation..

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Indications
  • Healing of Erosive or Ulcerative GERD in Adults
  • Rabeprazole is indicated for short-term (4 to 8 weeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (GERD). For those patients who have not healed after 8 weeks of treatment, an additional 8-week course of Rabeprazole may be considered.
  • Maintenance of Healing of Erosive or Ulcerative GERD in Adults
  • Rabeprazole is indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease (GERD Maintenance). Controlled studies do not extend beyond 12 months.
  • Treatment of Symptomatic GERD in Adults
  • Rabeprazole is indicated for the treatment of daytime and nighttime heartburn and other symptoms associated with GERD in adults for up to 4 weeks.
  • Healing of Duodenal Ulcers in Adults
  • Rabeprazole is indicated for short-term (up to four weeks) treatment in the healing and symptomatic relief of duodenal ulcers. Most patients heal within four weeks.
  • Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence in Adults
  • Rabeprazole, in combination with amoxicillin and clarithromycin as a three drug regimen, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or history within the past 5 years) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence.
  • In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted
  • Treatment of Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome in Adults
  • Rabeprazole is indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
  • Short-term Treatment of Symptomatic GERD in Adolescent Patients 12 Years of Age and Older
  • Rabeprazole is indicated for the treatment of symptomatic GERD in adolescents 12 years of age and above for up to 8 weeks.
Dosage
  • Healing of Erosive or Ulcerative GERD in Adults
  • The recommended adult oral dose is one Rabeprazole 20 mg Delayed-Release tablet to be taken once daily for four to eight weeks. For those patients who have not healed after 8 weeks of treatment, an additional 8-week course of Rabeprazole may be considered.
  • Maintenance of Healing of Erosive or Ulcerative GERD in Adults
  • The recommended adult oral dose is one Rabeprazole 20 mg Delayed-Release tablet to be taken once daily. Controlled studies do not extend beyond 12 months.
  • Treatment of Symptomatic GERD in Adults
  • The recommended adult oral dose is one Rabeprazole 20 mg Delayed-Release tablet to be taken once daily for 4 weeks. If symptoms do not resolve completely after 4 weeks, an additional course of treatment may be considered.
  • Healing of Duodenal Ulcers in Adults

The recommended adult oral dose is one ACIPHEX 20 mg Delayed-Release tablet to be taken once daily after the morning meal for a period up to four weeks [see Indications and Usage (1.5)]. Most patients with duodenal ulcer heal within four weeks. A few patients may require additional therapy to achieve healing.

  • Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence in Adults
  • Treatment of Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome in Adults
  • The dosage of ACIPHEX in patients with pathologic hypersecretory conditions varies with the individual patient. The recommended adult oral starting dose is 60 mg once daily. Doses should be adjusted to individual patient needs and should continue for as long as clinically indicated. Some patients may require divided doses. Doses up to 100 mg QD and 60 mg BID have been administered. Some patients with Zollinger-Ellison syndrome have been treated continuously with Rabeprazole for up to one year.
  • Short-term Treatment of Symptomatic GERD in Adolescent Patients 12 Years of Age and Older
  • The recommended oral dose for adolescents 12 years of age and older is one 20 mg Delayed-Release Tablet once daily for up to 8 weeks
  • Elderly, Renal, and Hepatic Impaired Patients
  • No dosage adjustment is necessary in elderly patients, in patients with renal disease, or in patients with mild to moderate hepatic impairment.

Administration of rabeprazole to patients with mild to moderate liver impairment resulted in increased exposure and decreased elimination. Due to the lack of clinical data on rabeprazole in patients with severe hepatic impairment, caution should be exercised in those patients.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

Condition1
  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Rabeprazole in adult patients.

Non–Guideline-Supported Use

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Rabeprazole in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Indications
  • Treatment of GERD in Pediatric Patients 1 to 11 Years of Age
  • Rabeprazole is indicated for treatment of GERD in children 1 to 11 years of age for up to 12 weeks.
Dosage
  • Treatment of GERD in Pediatric Patients 1 to 11 Years of Age
  • The recommended dosage of Rabeprazole for pediatric patients 1 to 11 years of age by body weight is:
:* Less than 15 kg: 5 mg once daily for up to 12 weeks with the option to increase to 10 mg if inadequate response.
:* 15 kg or more: 10 mg once daily for up to 12 weeks

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

Condition1
  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Rabeprazole in pediatric patients.

Non–Guideline-Supported Use

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Rabeprazole in pediatric patients.

Contraindications

  • Condition1

Warnings

  • Description

Precautions

  • Description

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Rabeprazole in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Rabeprazole in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

Drug Interactions

  • Drug
  • Description

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

  • Pregnancy Category


Pregnancy Category (AUS):

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Rabeprazole in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Rabeprazole during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Rabeprazole with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Rabeprazole with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Rabeprazole with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Rabeprazole with respect to specific gender populations.

Race

There is no FDA guidance on the use of Rabeprazole with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Rabeprazole in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Rabeprazole in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Rabeprazole in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Rabeprazole in patients who are immunocompromised.

Administration and Monitoring

Administration

  • Oral
  • Intravenous

Monitoring

There is limited information regarding Monitoring of Rabeprazole in the drug label.

  • Description

IV Compatibility

There is limited information regarding IV Compatibility of Rabeprazole in the drug label.

Overdosage

Acute Overdose

Signs and Symptoms

  • Description

Management

  • Description

Chronic Overdose

There is limited information regarding Chronic Overdose of Rabeprazole in the drug label.

Pharmacology

There is limited information regarding Rabeprazole Pharmacology in the drug label.

Mechanism of Action

Structure

File:Rabeprazole01.png
This image is provided by the National Library of Medicine.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Rabeprazole in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Rabeprazole in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Rabeprazole in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Rabeprazole in the drug label.

How Supplied

Storage

There is limited information regarding Rabeprazole Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Rabeprazole |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Rabeprazole |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Rabeprazole in the drug label.

Precautions with Alcohol

  • Alcohol-Rabeprazole interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

Look-Alike Drug Names

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. ↑ Empty citation (help)
  2. ↑ "http://www.ismp.org". External link in |title= (help)

{{#subobject: 

 |Page Name=Rabeprazole
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage={{{dosageValue}}} {{{dosageUnit}}}
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject: 

 |Label Page=Rabeprazole
 |Label Name=Rabeprazole11.png

}}

{{#subobject: 

 |Label Page=Rabeprazole
 |Label Name=Rabeprazole11.png

}}

Retrieved from "https://www.wikidoc.org/index.php?title=Rabeprazole&oldid=1054140"